Current concepts in the therapy of the spondyloarthritides

BioDrugs

Volumn 18, Issue 5, 2004, Pages 307-314

  Baraliakos, Xenofon ^a,b   Braun, Juergen ^a,b  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANEMIA; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BACKACHE; CLINICAL TRIAL; COLITIS; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; INFECTION; INTERVERTEBRAL DISK DEGENERATION; INTERVERTEBRAL DISK HERNIA; ISCHIALGIA; LIVER ENZYME ELEVATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; NEUROPATHY; PANCYTOPENIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SEPSIS; SIDE EFFECT; SPINE DISEASE; SPONDYLOARTHROPATHY; TUBERCULOSIS; UVEITIS; VASCULITIS;

CLINICAL TRIALS; DRUG THERAPY; FOLLOW-UP STUDIES; GERMANY; HUMANS; MULTICENTER STUDIES; SPONDYLARTHRITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 6044248855     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418050-00003     Document Type: Review

References (101)

1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41 (1): 58-67
2. Brandt J, Bollow M, Haberle J, et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999; 38 (9): 831-6
3. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985; 44 (6): 359-67
4. Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France: Societe de Rhumatologie de l'Ouest. J Rheumatol 1999; 26 (12): 2622-7
5. Lautermann D, Braun J. Ankylosing spondylitis: cardiac manifestations. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S11-5
6. Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000; 27 (3): 613-22
7. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999; 12 (4): 247-55
8. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S16-22
9. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24 (4): 737-51
10. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21 (1): 117-28
11. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002; 29 (7): 1420-5
12. van Tubergen A, Landewe R, van der Heijde D, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45 (5): 430-8
13. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002; 4 (5): 307-21
14. Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs 2003; 12 (7): 1097-109
15. Maini R, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65
16. Wagner CL, Schantz A, Barnathan E, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003; 112: 37-53
17. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348 (7): 601-8
18. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126(2): 402-13
19. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996; 8 (4): 275-87
20. McGonagle D, Gibbon W, O'Connor P, et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998; 41 (4): 694-700
21. Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37 (7): 1039-45
22. Muche B, Bollow M, Francois RJ, et al. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003; 48 (5): 1374-84
23. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60 (4): 316-21
24. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38 (4): 499-505
25. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59 (2): 135-40
26. Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1: sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol 1985; 12 (2): 287-93
27. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5 (2): 119-33
28. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003; 17 (2): 185-92
29. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59 (6): 428-33
30. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28 (7): 1605-14
31. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis (AS): results of a six-month open label study. Rheumatology (Oxford) 2002; 41(11): 1280-5
32. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48 (8): 2224-33
33. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61 (3): 207-12
34. Maksymowych WP, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29 (5): 959-65
35. Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD, et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann Rheum Dis 2003; 62 (12): 1239-40
36. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43 (6): 1346-52
37. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21(12): 2286-91
38. Braun J, Brandt J, Listing J, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. In press
39. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to TNF-α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63 (6): 665-70
40. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003; 62 (4): 347-9
41. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62 (12): 1218-20
42. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48 (4): 1126-36
43. Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44 (9): 2112-7
44. Gorman JD, Sack KE, Davis JC, et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346 (18): 1349-56
45. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48 (11): 3230-6
46. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48 (6): 1667-75
47. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S152-7
48. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48 (11): 3013-22
49. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098-104
50. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48 (8): 2122-7
51. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62 (9): 829-34
52. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46 (12): 3151-8
53. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44 (12): 2862-9
54. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116 (5): 305-11
55. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86 (2-3): 123-30
56. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43 (11): 2383-90
57. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48 (4): 1015-23
58. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359 (9306): 579-80
59. Cheifetz A, Michaud K, Anderson J, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98 (6): 1315-24
60. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50 (2): 372-9
61. Food and Drug Administration, Center for Biologies Evaluation and Research. Safety update on TNF-alpha antagonists: infliximab and etanercept [online]. Available from: www.fda.gov (Accessed 2001)
62. Manadan A, Mohan A, Cote TR, et al. Tuberculosis and etanercept treatment [abstract]. Arthritis and Rheumatism 2002; 46 Suppl. 9: 166
63. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344 (14): 1099-100
64. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48 (2): 319-24
65. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002; 46 (8): 2255-7
66. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46 (10): 2565-70
67. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138 (10); 807-11
68. DeBandt M, Descamps V, Meyer O. Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2001; 60: 175
69. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNFα-induced systemic lupus syndrome. Clin Rheumatol 2003; 22 (1): 56-61
70. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131 (8): 634
71. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002; 61 (9): 850-1
72. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30 (10): 2287-91
73. Olivieri I, Padula A, Ciancio G, et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61 (4): 375-6
74. Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46 (7): 1965-8
75. Braun J, Brandt J, Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313): 1187-93
76. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21 (12): 2281-5
77. Davis J, van der Heijde D, Dougados M, et al. Baseline factors influential on ASAS 20 response in ankylosing spondylitis patients treated with etanercept (ENBREL®). Arthritis and Rheumatism 2003; 48 (9 Suppl.): S440
78. Burke JG, Watson RW, McCormack D, et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg Br 2002; 84 (2): 196-201
79. Goupille P, Jayson MI, Valat JP, et al. The role of inflammation in disk herniation-associated radiculopathy. Semin Arthritis Rheum 1998; 28 (1): 60-71
80. Kawakami M, Tamaki T, Hayashi N, et al. Possible mechanism of painful radiculopathy in lumbar disc herniation. CHn Orthop 1998; (351): 241-51
81. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 1993; 18(11): 1425-32
82. Bobechko WP, Hirsch C. Auto-immune response to nucleus pulposus in the rabbit. J Bone Joint Surg Br 1965; 47: 574-80
83. Shubayev VI, Myers RR. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 2000; 855 (1): 83-9
84. Igarashi T, Kikuchi S, Shubayev V, et al. 2000 Volvo Award winner in basic science studies: exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats. Spine 2000; 25 (23): 2975-80
85. Byrod G, Rydevik B, Johansson BR, et al. Transport of epidurally applied horse-radish peroxidase to the endoneurial space of dorsal root ganglia: a light and electron microscopic study. J Peripher Nerv Syst 2000; 5 (4): 218-26
86. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23 (4): 339-46
87. Otani K, Aral I, Mao G, et al. Nucleus pulposus induced nerve root injury: relationship betwenn blood flow and nerve conduction velocity. J Neurosurg 1999; 45: 614-9
88. Aoki Y, Rydevik B, Kikuchi S, et al. Local application of disc-related cytokines on spinal nerve roots. Spine 2002; 27 (15): 1614-7
89. Okamoto K, Martin DP, Schmelzer JD, et al. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol 2001; 169 (2): 386-91
90. Olmarker K. Radicular pain: recent pathophysiologic concepts and therapeutic implications. Schmerz 2001; 15 (6): 425-9
91. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10 Suppl. 2: 81-90
92. Bluthe RM, Dantzer R, Kelley KW. Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor alpha in mice. Eur J Pharmacol 1991; 209 (3): 281-3
93. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385 (6618): 729-33
94. Baumgartner RA, Deramo VA, Beaven MA. Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. J Immunol 1996; 157 (9): 4087-93
95. Karppinen J, Korhonen T, Malmivaara A, et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine 2003; 28 (8): 750-3
96. Myers RR. 1994 ASRA lecture: the pathogenesis of neuropathic pain. Reg Anesth 1995; 20 (3): 173-84
97. Mixter W. Rupture of the intervertebral disk with involvement of the spinal canal. N Engl J Med 1934; 211: 210-5
98. Wells MR, Racis SP, Vaidya U. Changes in plasma cytokines associated with peripheral nerve injury. J Neuroimmunol 1992; 39 (3): 261-8.
99. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine 2001; 26 (8): 863-9
100. Amor B, Santos RS, Nahal R, et al. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21 (10): 1883-7
101. Jayson MI. Leonard Trask: the wonderful invalid: the first American description of ankylosing spondylitis. Arthritis Rheum 2003; 48 (3): 612-3